Aspector (@rnaiphd) 's Twitter Profile
Aspector

@rnaiphd

PhD in Biology, w background in academia, government and industry. Major focus: RNAi technology and its application in medicine & agriculture.

ID: 976413026646708224

calendar_today21-03-2018 10:59:41

309 Tweet

392 Followers

8 Following

Aspector (@rnaiphd) 's Twitter Profile Photo

Rare disease coalition...nice to see RNAi represented by $ALNY. Would be good to see other RNAi companies: $ARWR $SLN $DRNA rarecoalition.com

Aspector (@rnaiphd) 's Twitter Profile Photo

Financial Times David Crow mRNA could revolutionize medicine, but you may be missing part of the story: there is another technology, RNAi (Nobel 2006) that allows you to 'silence' specific mRNA and thus negate the effect of 'bad genes'; there are already a few RNAi drugs on the market, I expect more soon.

Aspector (@rnaiphd) 's Twitter Profile Photo

Higher blood levels of omega-3 fatty acids from prescription fish oil showed no effect on CV events. At least there is ARO-APOC3 & ANG3 to look forward to...$ARWR jamanetwork.com/journals/jamac…

Aspector (@rnaiphd) 's Twitter Profile Photo

$ARWR CA the master of 'damning with faint praise', when asked @ RBC about Vertex drug he said (paraphrasing): "Biology is hard, we are simple, Vertex approach is elegant" then following up with the blunter "stoichiometry is going to kill 'em"

Aspector (@rnaiphd) 's Twitter Profile Photo

$ARWR $DRNA Another LPa candidate, joining ARWR (Olpasiran) & SLN360 from $SLN Dicerna Pharmaceuticals announces that the FDA has accepted the IND application filed by Eli Lilly for LY3819469, which is an investigational GalXC RNAi candidate targeting the LPA gene

Eric Weinstein (@ericrweinstein) 's Twitter Profile Photo

*If* we are being visited, it is likely not with conventional propulsion. It is insane that we are not talking about this as possible new physics. The conversation will go right back to technology, security, skeptism etc. Anything but physical discussion of a physical phenomena.